English
Toxins for Antibody-Drug Conjugate Research Library
Toxins for Antibody-Drug Conjugate Research Library
Artikelnummer
MEXHY-L023-1
Verpackungseinheit
1 mg
Hersteller
MedChemExpress
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Description: Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide.
Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide.
The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 92 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.
Advantages:
Formulation: A collection of 92 ADC cytotoxins supplied as solid powder
Layout: 96-well storage tube or 96-well plate: 1st and 12th column are left empty.384-well plate: the first two columns and the last two columns are left empty.Compounds with different concentrations or dissolved in different solvents will be put on separate plates.This way of layout may increase the number of plates because there could be three solvents and three concentrations. If you have other requirements, please let us know.
Container: 96-well Storage Tubes with Rack
Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide.
The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 92 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.
Advantages:
- A unique collection of 92 ADC cytotoxins for targeted therapy research.
- Used to develop new antibody-drug conjugates targeting cancer.
- Bioactivity and safety confirmed by preclinical research and clinical trials.
- Structurally diverse, medicinally active, and cell permeable.
- More detailed compound information with structure, IC50, and brief introduction.
- NMR and HPLC validated to ensure high purity and quality.
- All compounds are in stock and continuously updated.
Formulation: A collection of 92 ADC cytotoxins supplied as solid powder
Layout: 96-well storage tube or 96-well plate: 1st and 12th column are left empty.384-well plate: the first two columns and the last two columns are left empty.Compounds with different concentrations or dissolved in different solvents will be put on separate plates.This way of layout may increase the number of plates because there could be three solvents and three concentrations. If you have other requirements, please let us know.
Container: 96-well Storage Tubes with Rack
| Artikelnummer | MEXHY-L023-1 |
|---|---|
| Hersteller | MedChemExpress |
| Hersteller Artikelnummer | HY-L023-1 |
| Green Labware | Nein |
| Verpackungseinheit | 1 mg |
| Mengeneinheit | STK |
| Produktinformation (PDF) |
|
| MSDS (PDF) |
|
Immer für Sie da
Dr. Andreas Bergmann
